Advanced Solid Tumors Harboring MAPK Pathway Alterations

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
QLH11906Phase 11 trial
Active Trials
NCT05488821UnknownEst. Jul 2025

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
Qilu PharmaceuticalQLH11906

Clinical Trials (1)

NCT05488821Qilu PharmaceuticalQLH11906

Safety, Tolerability and Pharmacokinetics Study of QLH11906 in Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.

Start: Jun 2022Est. completion: Jul 2025
Phase 1Unknown

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
4h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
4h ago

Office Administrator

SystImmune
4h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
4h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
4h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
4h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

Related Indications

Breast Cancer(577)Prostate Cancer(385)Non-small Cell Lung Cancer(378)Multiple Myeloma(359)Cancer(249)Advanced Solid Tumors(226)Acute Myeloid Leukemia(209)Neoplasms(199)Colorectal Cancer(171)Melanoma(170)